MA37894A1 - Protéines de fusion d'interleukine-2 et leurs utilisations - Google Patents
Protéines de fusion d'interleukine-2 et leurs utilisationsInfo
- Publication number
- MA37894A1 MA37894A1 MA37894A MA37894A MA37894A1 MA 37894 A1 MA37894 A1 MA 37894A1 MA 37894 A MA37894 A MA 37894A MA 37894 A MA37894 A MA 37894A MA 37894 A1 MA37894 A1 MA 37894A1
- Authority
- MA
- Morocco
- Prior art keywords
- fusion proteins
- interleukin
- methods
- present
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne en général des protéines de fusion d'immunoglobulines et d'interleukine-2 (il-2). De plus, la présente invention concerne des polynucléotides codant pour de telles protéines de fusion, et des vecteurs et cellules hôtes comprenant de tels polynucléotides. L'invention concerne en outre des procédés de production des protéines de fusion de l'invention, et leurs procédés d'utilisation dans le traitement d'une maladie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261681676P | 2012-08-10 | 2012-08-10 | |
PCT/EP2013/066516 WO2014023752A1 (fr) | 2012-08-10 | 2013-08-07 | Protéines de fusion d'interleukine-2 et leurs utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37894A1 true MA37894A1 (fr) | 2018-07-31 |
MA37894B1 MA37894B1 (fr) | 2020-01-31 |
Family
ID=48948417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37894A MA37894B1 (fr) | 2012-08-10 | 2013-08-07 | Protéines de fusion d'interleukine-2 et leurs utilisations |
Country Status (22)
Country | Link |
---|---|
US (4) | US20140044675A1 (fr) |
EP (1) | EP2882458B1 (fr) |
JP (1) | JP6526561B2 (fr) |
KR (1) | KR20150041628A (fr) |
CN (2) | CN104507504A (fr) |
AR (1) | AR092089A1 (fr) |
AU (1) | AU2013301562B2 (fr) |
BR (1) | BR112015002765A2 (fr) |
CA (1) | CA2873291A1 (fr) |
CL (1) | CL2014003322A1 (fr) |
CO (1) | CO7121348A2 (fr) |
CR (1) | CR20140532A (fr) |
EA (1) | EA201500206A1 (fr) |
HK (1) | HK1208827A1 (fr) |
IL (1) | IL236933A0 (fr) |
MA (1) | MA37894B1 (fr) |
MX (1) | MX2015001749A (fr) |
PE (1) | PE20150752A1 (fr) |
PH (1) | PH12014502767A1 (fr) |
SG (1) | SG11201407579QA (fr) |
TW (1) | TW201420607A (fr) |
WO (1) | WO2014023752A1 (fr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3075745B1 (fr) | 2011-02-10 | 2018-09-05 | Roche Glycart AG | Polypeptides interleukin-2 mutants |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
CA2894511C (fr) | 2012-12-11 | 2021-12-07 | Albert Einstein College Of Medicine Of Yeshiva University | Procedes pour identification de recepteur/ligand a rendement eleve |
PT3102595T (pt) | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
MA40094B1 (fr) * | 2014-08-06 | 2022-05-31 | Univ Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
WO2016025385A1 (fr) | 2014-08-11 | 2016-02-18 | Delinia, Inc. | Variants d'il-2 modifiés qui activent sélectivement les cellules t régulatrices pour le traitement de maladies auto-immunes |
EP3428193B1 (fr) * | 2015-08-06 | 2020-09-30 | Agency For Science, Technology And Research | Anticorps anti-il-2-r beta/chaîne gamma commune |
US10144768B2 (en) | 2015-12-04 | 2018-12-04 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
KR20190019068A (ko) | 2016-05-18 | 2019-02-26 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
EP3458095A4 (fr) | 2016-05-18 | 2019-11-27 | Albert Einstein College of Medicine | Variants de polypeptides pd-l1, polypeptides multimères modulateurs des lymphocytes t et procédés d'utilisation correspondants |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
EP3534947A1 (fr) | 2016-11-03 | 2019-09-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
EP3558339B1 (fr) | 2016-12-22 | 2024-01-24 | Cue Biopharma, Inc. | Polypeptides multimères modulateurs des lymphocytes t et leurs méthodes d'utilisation |
EP3565829A4 (fr) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation |
IL269000B2 (en) | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
CN108623693B (zh) * | 2017-03-20 | 2022-03-25 | 徐寒梅 | 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用 |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
EP3630813A1 (fr) | 2017-05-24 | 2020-04-08 | Novartis AG | Protéines greffées d'anticorps-cytokine et procédés d'utilisation dans le traitement du cancer |
AU2018390418B2 (en) | 2017-12-19 | 2023-12-21 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
WO2019139896A1 (fr) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation |
US20210052727A1 (en) * | 2018-01-24 | 2021-02-25 | Beijing Percans Oncology Co., Ltd. | Cytokine fusion proteins |
WO2019158764A1 (fr) | 2018-02-16 | 2019-08-22 | Iltoo Pharma | Utilisation de l'interleukine 2 pour traiter le syndrome de sjögren |
EP3774861A1 (fr) | 2018-03-28 | 2021-02-17 | Bristol-Myers Squibb Company | Protéines de fusion de l'interleukine-2/du récepteur alpha de l'interleukine-2 et procédés d'utilisation |
US11845797B2 (en) | 2018-07-03 | 2023-12-19 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
WO2020007937A1 (fr) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Utilisation de l'interleukine-2 pour le traitement de la sclérose systémique |
EP3836954A1 (fr) | 2018-08-13 | 2021-06-23 | Iltoo Pharma | Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci |
JP7479383B2 (ja) * | 2018-09-27 | 2024-05-08 | エクシリオ デベロップメント, インコーポレイテッド | マスクされたサイトカインポリペプチド |
WO2020127277A1 (fr) | 2018-12-18 | 2020-06-25 | Robert Koch-Institut | Cellule présentatrice du cmh-i chargée de peptides et il-2 présentant une demi-vie prolongée pour amplifier une réponse immunitaire cytotoxique cellulaire |
EP4114440A1 (fr) | 2020-03-06 | 2023-01-11 | Centre Hospitalier Universitaire de Nimes | Interleukine-2 humaine à faible dose pour le traitement de la sclérose latérale amyotrophique |
KR20230009872A (ko) | 2020-05-12 | 2023-01-17 | 큐 바이오파마, 인크. | 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법 |
AU2021273009A1 (en) | 2020-05-13 | 2022-12-15 | Bonum Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
CN113912734A (zh) * | 2020-07-08 | 2022-01-11 | 南京师范大学 | 融合多肽及其用途 |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
JP2023548045A (ja) | 2020-10-23 | 2023-11-15 | アッシャー バイオセラピューティクス, インコーポレイテッド | 免疫細胞機能をモジュレートするためのcd8抗原結合分子を有する融合物 |
CN112724259B (zh) * | 2020-11-16 | 2022-12-20 | 天津林达生物科技有限公司 | 人血清白蛋白与白介素2的融合蛋白及其用途 |
CN116284380A (zh) * | 2021-05-14 | 2023-06-23 | 厦门柏慈生物科技有限公司 | 白细胞介素2结合分子、其衍生物、试剂盒及其生产方法和用途 |
WO2024008126A1 (fr) * | 2022-07-06 | 2024-01-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Mutéines d'il2 et leurs utilisations |
CN117003852A (zh) * | 2022-07-07 | 2023-11-07 | 北京大学 | 白细胞介素-2的拓扑改造及其作为自身免疫病药物的应用 |
WO2024056154A1 (fr) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukine-2 pour le traitement des troubles du spectre autistique |
KR20240055222A (ko) * | 2022-10-19 | 2024-04-29 | 주식회사 에이프릴바이오 | 인터루킨-2 변이 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도 |
CN117986383A (zh) * | 2022-11-02 | 2024-05-07 | 北京昌平实验室 | 融合蛋白及其应用 |
WO2024121173A1 (fr) | 2022-12-05 | 2024-06-13 | Centre Hospitalier Universitaire De Nimes | Interleukine-2 humaine à faible dose pour traitement de la sclérose latérale amyotrophique dans un sous-groupe de patients |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2388385B1 (fr) | 1977-04-18 | 1982-01-08 | Hitachi Metals Ltd | Piece d'ornement fixee par des aimants permanents |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
JPS60502136A (ja) * | 1983-08-10 | 1985-12-12 | アムジエン インコーポレイテツド | 微生物によるインタ−ル−キン2の形質発現 |
WO1985000817A1 (fr) | 1983-08-10 | 1985-02-28 | Amgen | Expression microbienne de l'interleukine ii |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
CA2103059C (fr) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Methode de production d'anticorps humanises |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
HUP0100813A3 (en) * | 1998-02-25 | 2003-08-28 | Lexigen Pharmaceuticals Corp L | Enhancing the circulating half-life of antibody-based fusion proteins |
US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
MXPA04005266A (es) | 2001-12-04 | 2004-10-11 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada. |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
WO2005007121A2 (fr) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Polypeptides de l'interleukine-2(il-2) mutante |
US20060234205A1 (en) | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
AU2005230848B9 (en) | 2004-03-31 | 2011-06-02 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
ES2403055T3 (es) | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
US20060110398A1 (en) * | 2004-11-24 | 2006-05-25 | Schering Corporation | DAP-10 and uses thereof |
CA2656700A1 (fr) * | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions et procedes destines a ameliorer l'efficacite de reponses immunitaires a mediation par il-2 |
JP2010534469A (ja) | 2007-07-25 | 2010-11-11 | アストラゼネカ アクチボラグ | Kdr指向性標的化結合物質およびその使用 |
WO2009061853A2 (fr) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Polypeptides d'interleukine-2 (il-2) mutants |
JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | pIX又はpVIIへの融合を介したヒトデノボpIXファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
WO2010085495A1 (fr) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions et procédés de traitement de maladies inflammatoires et auto-immunes |
UA113712C2 (xx) | 2010-08-13 | 2017-02-27 | Антитіло до fap і способи його застосування | |
CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
EP3075745B1 (fr) | 2011-02-10 | 2018-09-05 | Roche Glycart AG | Polypeptides interleukin-2 mutants |
EP3766513A1 (fr) | 2011-03-11 | 2021-01-20 | Assistance Publique Hôpitaux de Paris | Utilisation de dosages faibles d'il-2 pour traiter la vascularite |
KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
EP3626739A1 (fr) | 2011-06-24 | 2020-03-25 | Stephen D. Gillies | Protéines de fusion d'immunoglobuline à chaîne légère et leurs procédés d'utilisation |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
PT3102595T (pt) | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
MA40094B1 (fr) | 2014-08-06 | 2022-05-31 | Univ Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
-
2013
- 2013-08-06 US US13/960,149 patent/US20140044675A1/en not_active Abandoned
- 2013-08-07 MA MA37894A patent/MA37894B1/fr unknown
- 2013-08-07 CN CN201380041053.1A patent/CN104507504A/zh active Pending
- 2013-08-07 AU AU2013301562A patent/AU2013301562B2/en not_active Ceased
- 2013-08-07 BR BR112015002765A patent/BR112015002765A2/pt active Search and Examination
- 2013-08-07 MX MX2015001749A patent/MX2015001749A/es unknown
- 2013-08-07 JP JP2015525869A patent/JP6526561B2/ja not_active Expired - Fee Related
- 2013-08-07 KR KR20157003397A patent/KR20150041628A/ko not_active Application Discontinuation
- 2013-08-07 WO PCT/EP2013/066516 patent/WO2014023752A1/fr active Application Filing
- 2013-08-07 SG SG11201407579QA patent/SG11201407579QA/en unknown
- 2013-08-07 EA EA201500206A patent/EA201500206A1/ru unknown
- 2013-08-07 EP EP13745844.4A patent/EP2882458B1/fr active Active
- 2013-08-07 CN CN202010331382.1A patent/CN111635460A/zh active Pending
- 2013-08-07 CA CA2873291A patent/CA2873291A1/fr not_active Abandoned
- 2013-08-07 PE PE2014002251A patent/PE20150752A1/es not_active Application Discontinuation
- 2013-08-09 AR ARP130102839A patent/AR092089A1/es unknown
- 2013-08-09 TW TW102128732A patent/TW201420607A/zh unknown
-
2014
- 2014-10-31 CO CO14241630A patent/CO7121348A2/es unknown
- 2014-11-20 CR CR20140532A patent/CR20140532A/es unknown
- 2014-12-04 CL CL2014003322A patent/CL2014003322A1/es unknown
- 2014-12-10 PH PH12014502767A patent/PH12014502767A1/en unknown
-
2015
- 2015-01-26 IL IL236933A patent/IL236933A0/en unknown
- 2015-10-02 HK HK15109669.4A patent/HK1208827A1/xx unknown
- 2015-12-11 US US14/967,019 patent/US20160090407A1/en not_active Abandoned
-
2017
- 2017-09-05 US US15/695,899 patent/US10562949B2/en not_active Expired - Fee Related
-
2020
- 2020-02-05 US US16/783,141 patent/US11365232B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EA201500206A1 (ru) | 2016-04-29 |
US11365232B2 (en) | 2022-06-21 |
BR112015002765A2 (pt) | 2018-03-13 |
PH12014502767A1 (en) | 2015-02-09 |
MA37894B1 (fr) | 2020-01-31 |
US20160090407A1 (en) | 2016-03-31 |
HK1208827A1 (en) | 2016-03-18 |
AU2013301562B2 (en) | 2017-04-06 |
CL2014003322A1 (es) | 2015-02-13 |
EP2882458A1 (fr) | 2015-06-17 |
MX2015001749A (es) | 2015-06-05 |
CA2873291A1 (fr) | 2014-02-13 |
US20140044675A1 (en) | 2014-02-13 |
CN104507504A (zh) | 2015-04-08 |
CR20140532A (es) | 2015-01-12 |
KR20150041628A (ko) | 2015-04-16 |
SG11201407579QA (en) | 2014-12-30 |
PE20150752A1 (es) | 2015-05-15 |
IL236933A0 (en) | 2015-03-31 |
US20180009868A1 (en) | 2018-01-11 |
WO2014023752A1 (fr) | 2014-02-13 |
AR092089A1 (es) | 2015-03-25 |
EP2882458B1 (fr) | 2018-07-11 |
US20200172591A1 (en) | 2020-06-04 |
US10562949B2 (en) | 2020-02-18 |
CN111635460A (zh) | 2020-09-08 |
AU2013301562A1 (en) | 2014-11-20 |
JP6526561B2 (ja) | 2019-06-05 |
JP2015530984A (ja) | 2015-10-29 |
TW201420607A (zh) | 2014-06-01 |
CO7121348A2 (es) | 2014-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37894A1 (fr) | Protéines de fusion d'interleukine-2 et leurs utilisations | |
MA20150232A1 (fr) | Protéines de fusion de l'interleukine-10 et leurs utilisations | |
MA38308A1 (fr) | Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t | |
MA38406B1 (fr) | Virus de la maladie de newcastle et leurs utilisations | |
CA2868907C (fr) | Anticorps anti-hla-b*27 et leurs utilisations | |
MA35130B1 (fr) | Composition comprenant de l'aflibercept, de l'acide folinique, du 5-fluoro-uracile (5-fu) et de l'irinocetan (folfiri) | |
EA201590910A1 (ru) | Белки на основе структурного домена фибронектина, связывающие pcsk9 | |
EA201690567A1 (ru) | Антитела против pd1 и их применение в качестве терапевтических и диагностических средств | |
IN2014KN02929A (fr) | ||
EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
MA34555B1 (fr) | Nouvelles protéines de liaison à un antigène | |
MA34521B1 (fr) | Polypeptides de relaxine modifiés et leurs utilisations | |
MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
IN266744B (fr) | ||
MA44922A1 (fr) | Anticorps | |
MX2015005384A (es) | Miembros de union para il-1 beta. | |
MA40283A (fr) | Aptamères spécifiques du récepteur tlr-4 et leurs utilisations | |
MX2018000447A (es) | Novedosas proteinas especificas para lag-3. | |
MA39096B1 (fr) | Anticorps spécifiques à fcrn | |
FR2986229B1 (fr) | Nouveaux monergols ioniques a base de n2o pour la propulsion spatiale | |
MX2015005313A (es) | Elucion de biomoleculas de resinas multimodales utilizando mes y mops como modificadores de fase movil. | |
WO2015010791A3 (fr) | Nouveaux anticorps pour le diagnostic et le traitement de la polyarthrite rhumatoïde | |
MA35457B1 (fr) | Nouvelles formulations de pyriméthanil et leur utilisations dans le traitement des cultures | |
MA39190A1 (fr) | Dérivés d'imidazolyle fusionnés, leur préparation et leur utilisation en tant que médicaments | |
MA46819B1 (fr) | Streptococcus thermophilus pour utilisation dans la préparation de produits fermentés |